A Study to Evaluate the Effectiveness of the Additional Risk Minimisation Measures (aRMMs) for REBLOZYL Among Healthcare Professionals (HCPs) in the European Economic Area (EEA)
Latest Information Update: 22 Jul 2024
Price :
$35 *
At a glance
- Drugs Luspatercept (Primary)
- Indications Beta-thalassaemia; Myelodysplastic syndromes; Myelofibrosis
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 01 Sep 2022 Status changed from active, no longer recruiting to completed.
- 04 Aug 2022 Status changed from not yet recruiting to active, no longer recruiting.
- 30 Jul 2021 New trial record